Literature DB >> 7400329

Human coagluation factor V purification and thrombin-catalyzed activation.

B Dahlbäck.   

Abstract

Factor V was isolated from human plasma by barium citrate adsorption, polyethylene glycol fractionation, DEAE-Sepharose CL-6B chromatography, ammonium sulfate fractionation, and gel chromatography on Ultrogel 22. Degradation of Factor V during purification was largely prevented by ample use of inhibitors of proteolytic enzyme. The purified Factor V was a stable, single-chain molecule with an apparent molecular weight of 330,000. Activation of human Factor V by thrombin resulted in a 10- to 15-fold increase in activity. The activation pattern as monitored by sodium dodecyl sulfate polyacrylamide gel electrophoresis was compared with that of bovine Factor V. Differences in the patterns of thrombin activation were noticed between the two species, whereas the final products were similar. The products of human Factor V activation are two closely spaced doublets, one with an apparent molecular weight of approximately 110,000, and the other, approximately 72,000. An antibody was raised against the purified protein. Crossed immunoelectrophoresis showed that the antibody recognized Factor V both before and after activation with thrombin.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7400329      PMCID: PMC371687          DOI: 10.1172/JCI109890

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  Preparation and partial characterization of two forms of bovine thrombin.

Authors:  R L Lundblad; L C Uhteg; C N Vogel; H S Kingdon; K G Mann
Journal:  Biochem Biophys Res Commun       Date:  1975-09-16       Impact factor: 3.575

2.  Agarose gel electrophoresis.

Authors:  B G Johansson
Journal:  Scand J Clin Lab Invest Suppl       Date:  1972

3.  Crossed immunoelectrophoresis.

Authors:  P O Ganrot
Journal:  Scand J Clin Lab Invest Suppl       Date:  1972

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  The localization of factor V within normal human platelets and the demonstration of a platelet-factor V antigen in congenital factor V deficiency.

Authors:  K Breederveld; J C Giddings; J W ten Cate; A L Bloom
Journal:  Br J Haematol       Date:  1975-03       Impact factor: 6.998

Review 6.  Prothrombin structure, activation, and biosynthesis.

Authors:  J W Suttie; C M Jackson
Journal:  Physiol Rev       Date:  1977-01       Impact factor: 37.312

7.  Factor V activity of platelets: evidence for an activated factor V molecule and for a platelet activator.

Authors:  B Osterud; S I Rapaport; K K Lavine
Journal:  Blood       Date:  1977-05       Impact factor: 22.113

8.  Factor V.

Authors:  R W Colman; R M Weinberg
Journal:  Methods Enzymol       Date:  1976       Impact factor: 1.600

9.  The activation of factor V by factor Xa or alpha-chymotrypsin and comparison with thrombin and RVV-V action. An improved factor V isolation procedure.

Authors:  C M Smith; D J Hanahan
Journal:  Biochemistry       Date:  1976-05-04       Impact factor: 3.162

10.  Activation of human prothrombin by highly purified human factors V and X-a in presence of human antithrombin.

Authors:  J S Rosenberg; D L Beeler; R D Rosenberg
Journal:  J Biol Chem       Date:  1975-03-10       Impact factor: 5.157

View more
  16 in total

1.  Reevaluation of the role of HDL in the anticoagulant activated protein C system in humans.

Authors:  Cecilia Oslakovic; Eva Norstrøm; Björn Dahlbäck
Journal:  J Clin Invest       Date:  2010-05       Impact factor: 14.808

2.  Novel role for galectin-8 protein as mediator of coagulation factor V endocytosis by megakaryocytes.

Authors:  Claudia Zappelli; Carmen van der Zwaan; Daphne C Thijssen-Timmer; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

3.  Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V.

Authors:  B Dahlbäck; B Hildebrand
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

4.  Active site-labeled prothrombin inhibits prothrombinase in vitro and thrombosis in vivo.

Authors:  Heather K Kroh; Peter Panizzi; Svetlana Tchaikovski; T Regan Baird; Nancy Wei; Sriram Krishnaswamy; Guido Tans; Jan Rosing; Bruce Furie; Barbara C Furie; Paul E Bock
Journal:  J Biol Chem       Date:  2011-04-29       Impact factor: 5.157

5.  Functional role of the polysaccharide component of rabbit thrombomodulin proteoglycan. Effects on inactivation of thrombin by antithrombin, cleavage of fibrinogen by thrombin and thrombin-catalysed activation of factor V.

Authors:  M C Bourin; U Lindahl
Journal:  Biochem J       Date:  1990-09-01       Impact factor: 3.857

6.  The role of thrombin exosites I and II in the activation of human coagulation factor V.

Authors:  Kenneth Segers; Björn Dahlbäck; Paul E Bock; Guido Tans; Jan Rosing; Gerry A F Nicolaes
Journal:  J Biol Chem       Date:  2007-09-18       Impact factor: 5.157

7.  A phosphatidylserine binding site in factor Va C1 domain regulates both assembly and activity of the prothrombinase complex.

Authors:  Rinku Majumder; Mary Ann Quinn-Allen; William H Kane; Barry R Lentz
Journal:  Blood       Date:  2008-06-27       Impact factor: 22.113

Review 8.  The molecular basis of factor V and VIII procofactor activation.

Authors:  R M Camire; M H A Bos
Journal:  J Thromb Haemost       Date:  2009-09-18       Impact factor: 5.824

9.  Heterogeneity of human factor V deficiency. Evidence for the existence of antigen-positive variants.

Authors:  H C Chiu; E Whitaker; R W Colman
Journal:  J Clin Invest       Date:  1983-08       Impact factor: 14.808

10.  Activation of coagulation factor V by a platelet protease.

Authors:  W H Kane; J S Mruk; P W Majerus
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.